Related Experiment Video
Updated: May 6, 2026
07:27
Transcriptome Analysis of Single Cells
Published on: April 25, 2011
30.3K
Author Correction: Single-cell transcriptomic analysis of Alzheimer's disease
Hansruedi Mathys1,2, Jose Davila-Velderrain3,4, Zhuyu Peng1,2
1Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nature
|June 19, 2019
Summary
This study corrects acknowledgment and data errors in a previous article, ensuring accurate funding attribution and data presentation for Alzheimer's research.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Context:
- Previous research on Alzheimer's disease pathology.
- Need for accurate data reporting and funding acknowledgment.
Purpose:
- To correct errors in the acknowledgment section and supplementary data.
- To ensure the integrity of published scientific findings.
Summary:
- Corrected acknowledgment to include support from the Cure Alzheimer's Fund (CAF).
- Updated NIH grant number from RF1AG054012 to U01MH119509.
- Reversed and corrected column labels in Supplementary Table 2 for accurate pathology data.
Impact:
- Enhances the transparency and reproducibility of the research.
- Ensures proper attribution of funding sources.
- Improves the accuracy of presented Alzheimer's pathology data.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
01:23Alzheimer Disease ll: Pathophysiology
44
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44